GKOS · Company research
Glaukos Corporation (GKOS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
23records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Forge’s Fierce Life Sciences Announces 2026 Fierce Innovation Awards Finalists and Unveils the Fierce Vanguard Gala | Forge's Fierce Life Sciences announced finalists for the 2026 Fierce Life Science and Healthcare Innovation Awards, recognizing breakthrough innovations across AI, biotechnology, digital health, and medical devices. The inaugural Fierce Vanguard Gala on November 19, 2026, in New York City will consolidate three recognition programs (Fierce 50, Fierce 15, and Innovation Awards) and announce winners live. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | bullish | 1 | 1 |
| Glaukos (NYSE:GKOS): High Growth Momentum Meets a Breakout Setup - ChartMill | Glaukos (NYSE:GKOS): High Growth Momentum Meets a Breakout Setup ChartMill | View source ↗ | ChartMill | Oct 17, 2026 | neutral | 0 | 0.6 |
| Who's Buying or Selling Glaukos Corp (GKOS) Stock Today? - GuruFocus | Who's Buying or Selling Glaukos Corp (GKOS) Stock Today? GuruFocus | View source ↗ | GuruFocus | Oct 16, 2026 | neutral | 0 | 0.6 |
| Glaukos Corporation (GKOS) Stock Price, News, Quote & History - Yahoo! Finance Canada | Glaukos Corporation (GKOS) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| Glaukos Corporation (GKOS) Stock Forecasts - Yahoo Finance | Glaukos Corporation (GKOS) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? | Glaukos Corporation (GKOS) shares have gained 36.8% over six months, outperforming its industry, driven by strong Q2 results with 50% revenue growth to $185.6 million, successful commercial expansion of Epioxa for keratoconus treatment, positive clinical data for iDose TR, and pipeline advances including a new retinal disease licensing agreement. The company raised its 2026 revenue guidance to $680-$700 million. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - TradingView | Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? TradingView | View source ↗ | TradingView | Oct 14, 2026 | neutral | 0 | 0.6 |
| Glaukos Corporation (GKOS) Stock Forecasts - Yahoo! Finance Canada | Glaukos Corporation (GKOS) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 10, 2026 | neutral | 0 | 0.6 |
| Glaukos: The Second J-Code Rewrites The Risk Math - Seeking Alpha | Glaukos: The Second J-Code Rewrites The Risk Math Seeking Alpha | View source ↗ | Seeking Alpha | Oct 10, 2026 | neutral | 0 | 0.6 |
| Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - The Globe and Mail | Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal The Globe and Mail | View source ↗ | The Globe and Mail | Oct 9, 2026 | neutral | 0 | 0.6 |
| Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal | Glaukos Corporation announced a licensing agreement with RevOpsis Therapeutics to develop RO-104, a first-in-class tri-specific biologic for retinal diseases, and gained exclusive access to the RevMod platform for up to four additional retinal biologic candidates. Despite the strategic expansion, GKOS stock declined 6.3% following the announcement, though it has gained 42.8% year-to-date. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal | Glaukos Corporation announced a licensing agreement with RevOpsis Therapeutics to develop RO-104, a first-in-class tri-specific biologic for retinal diseases, and gained exclusive access to the RevMod platform for up to four additional retinal biologic candidates. Despite the strategic expansion, GKOS stock declined 6.3% following the announcement, though it has gained 42.8% year-to-date. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Adding an eye treatment to cataract surgery lowered pressure more than surgery alone. - Stock Titan | Adding an eye treatment to cataract surgery lowered pressure more than surgery alone. Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| Glaukos (GKOS) Shares Fall 13% Despite Positive Epioxa Trial Res - GuruFocus | Glaukos (GKOS) Shares Fall 13% Despite Positive Epioxa Trial Res GuruFocus | View source ↗ | GuruFocus | Oct 8, 2026 | neutral | 0 | 0.6 |
| Glaukos stock slips after insider selling (GKOS:NYSE) - Seeking Alpha | Glaukos stock slips after insider selling (GKOS:NYSE) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 8, 2026 | neutral | 0 | 0.6 |
| A new license lets Glaukos pursue up to four more potential retinal treatments - Stock Titan | A new license lets Glaukos pursue up to four more potential retinal treatments Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| Why Glaukos (GKOS) Stock Is Up Today - Quiver Quantitative | Why Glaukos (GKOS) Stock Is Up Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 7, 2026 | neutral | 0 | 0.6 |
| Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise? | Intuitive Surgical's single-port (SP) platform is emerging as a significant growth franchise with 61% year-over-year procedure growth and an installed base of 445 systems. Strong U.S. utilization gains (25% YoY) and expanding stapler adoption (nearly 60% of eligible cases) support the platform's trajectory toward becoming a billion-dollar business. The company is also expanding internationally and through product innovation. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| A live webcast on Glaukos's third-quarter results is set for Oct. 28 at 1:30 p.m. PT. - Stock Titan | A live webcast on Glaukos's third-quarter results is set for Oct. 28 at 1:30 p.m. PT. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| If You Invested $1000 In Glaukos Stock 10 Years Ago, You Would Have This Much Today - Benzinga | If You Invested $1000 In Glaukos Stock 10 Years Ago, You Would Have This Much Today Benzinga | View source ↗ | Benzinga | Oct 6, 2026 | neutral | 0 | 0.6 |
| Glaukos (NYSE:GKOS) Stock Forecast & Analyst Predictions - Simply Wall Street | Glaukos (NYSE:GKOS) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 1, 2026 | neutral | 0 | 0.6 |
| Glaukos (GKOS) Stock Looks Fully Priced Against Its Sales Growth Story - Yahoo Finance | Glaukos (GKOS) Stock Looks Fully Priced Against Its Sales Growth Story Yahoo Finance | View source ↗ | Yahoo Finance | Sep 23, 2026 | neutral | 0 | 0.6 |
| Glaukos Corporation (GKOS) Stock Rises on Q2 2026 Earnings - Quiver Quantitative | Glaukos Corporation (GKOS) Stock Rises on Q2 2026 Earnings Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 29, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.